EPICART – DNA methylation signature for CAR T cell therapy

MISSION

To predict the response to a CART therapy before the infusion of the cells, preventing unwanted adverse reactions.

Diagnostics/Therapeutics

Signature validation in clinical assay

Patients with B-cell malignancies before the treatment with CART19 cells.

THE PROBLEM

Chemotherapy is the first line of therapy B-cell malignancies, being highly unspecific and with high relapsed-redractory (r/r) rates
Novel therapeutic alternatives have emerged, such as CAR T-cells
Despite the favourable expectations, CARTs are associated with different toxicities
The treatment and the post-treatment care are very costly

THE SOLUTION

EPICART is an identified epigenetic signature from pre-infused CAR T-cells capable of predicting the outcome of the patients (OS- and EFS-probabilities)
The signature can predict the probability of a patient to develop side effects or a nonresponsive outcome
EPICART will prevent high-risk CART interventions enabling clinicians and healthcare systems to improve their clinical decisions

COMPETITIVE ADVANTAGE

EPICART is the first diagnostic tool predicting the outcome of a CART treatment before its commencement
Cost-effective and with a minimal invasion of the patient
Early prognosis - Reduced risk
Reduced costs

ADDITIONAL INFO

Type of licence: exclusive licence
License royalties: between 3%-5% depending on the revenues
Ownership of technology: INSTITUT JOSEP CARRERAS 69,9 % ICREA 13,6 % BSC-CNS 16,5 %
Better fortune clause
Ownership of the future innovation rights, depending on by who has been developed
Applicable law would be Spanish and Barcelona jurisdiction.

TIME LIMIT TO APPLY: 26th April 2024